Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Am J Psychiatry. 2013 Sep 1;170(9):10.1176/appi.ajp.2013.12091163. doi: 10.1176/appi.ajp.2013.12091163

Table 1.

Significant Individual HTR3A and HTR3B SNP Associations with Three Drinking Measuresa

Gene SNP Genotype Population Carrying the Genotype Combination (% in Total Cohort) Outcome Measure: Estimated Mean Difference (95% CI) and p-Value
Reference Associated DDD PHDD PDA
HTR3B rs17614942 AA/CC AC O=17/135
P=19/139
(13%)		 −2.73
(−4.59 to −0.87)
0.004		 −20.45%
(−37.58% to −3.32%)
0.019		 17.95%
(0.95% to 34.95%)
0.039
HTR3A rs1150226 AA/GG AG O=20/135
P=24/139
(16%)		 −1.81
(−3.51 to −0.12)
0.036		 −20.65%
(−36.17% to −5.12%)
0.009		 19.75%
(4.30% to 35.19%)
0.012
rs1176713 AA/AG GG O=6/134
P=9/139
(5%)		 −3 87
(−6.95 to −0.78)
0.014		 −23 98%
(−51.83% to 3.87%)
0.091		 18.20%
(−9.31% to 45.70%)
0.195
a

All comparisons are between the ondansetron and placebo groups.

SNP=single-nucleotide polymorphism; CI=confidence interval; O=ondansetron; P=placebo; DDD=drinks per drinking day; PHDD=percentage of heavy drinking days; PDA=percentage of days abstinent.